secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061558
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024
--------------------------------------------------------------------

- Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.
- Cash and equivalents $43.0M as of Sept 30, 2023; expected to fund operations into Q2 2024.
- R&D expenses $5.8M (+7.4% YoY) driven by CAN-2409 manufacturing and regulatory work.
- G&A expenses $3.0M (-14.3% YoY) due to lower professional service and consulting costs.
- Topline overall survival data for CAN-2409 in NSCLC expected Q2 2024; prostate cancer data in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/0000950170-23-061558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/cadl-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer